Variable | No. (%) | P value | |
---|---|---|---|
Community-genotype ST72 MRSA cohort (n = 198) | Hospital-genotype ST5 / ST239 MRSA cohort (n = 156) | ||
Female gender | 77 (38.9) | 61 (39.1) | 0.967 |
Age, median (IQR) | 53.0 (4.0–65.0) | 65.5 (52.8–71.8) | 0.177 |
Reason for nasal MRSA screening | |||
Transfer from other hospital | 68 (34.3) | 60 (38.5) | 0.423 |
Pre-operative screening | 80 (40.4) | 39 (25.0) | 0.002 |
MRSA isolated from clinical specimens | 22 (11.1) | 10 (6.4) | 0.139 |
Carriage of vancomycin-resistant Enterococcus | 10 (5.1) | 13 (8.3) | 0.213 |
Undergoing HD or CAPD | 9 (4.5) | 6 (3.8) | 0.746 |
Location before admission | 0.520 | ||
Tertiary hospital | 141 (71.2) | 113 (72.4) | |
Home | 34 (17.2) | 26 (16.7) | |
General hospital | 19 (9.6) | 11 (7.1) | |
Chronic care facility | 4 (2.0) | 6 (3.8) | |
Admission due to infection other than MRSA infection | 32 (16.2) | 39 (25.0) | 0.039 |
Comorbidity | |||
Solid tumor | 48 (24.2) | 24 (15.4) | 0.040 |
Cardiovascular disease | 40 (20.2) | 33 (21.2) | 0.826 |
Diabetes mellitus | 26 (13.1) | 32 (20.5) | 0.062 |
Liver disease | 21 (10.6) | 14 (9.0) | 0.610 |
Neurologic disease | 20 (10.1) | 24 (15.4) | 0.135 |
Chronic kidney disease | 19 (9.6) | 21 (13.5) | 0.254 |
Solid organ transplantation | 7 (3.5) | 3 (1.9) | 0.522 |
Chronic lung disease | 5 (2.5) | 10 (6.4) | 0.072 |
Hematologic malignancy | 4 (2.0) | 11 (7.1) | 0.031 |
CAPD | 0 (0.0) | 3 (1.9) | 0.085 |
HSCT | 0 (0.0) | 1 (0.6) | 0.441 |
Severity of underlying disease | 0.651 | ||
Rapidly fatal | 9 (4.6) | 5 (3.2) | |
Ultimately fatal | 102 (51.5) | 76 (48.7) | |
Nonfatal | 87 (43.9) | 75 (48.7) |